Fearn Amy, Sheerin Neil Stephen
Amy Fearn, Neil Stephen Sheerin, Institute of Cellular Medicine, Newcastle University, NE2 4HH Tyne and Wear, United Kingdom.
World J Nephrol. 2015 Feb 6;4(1):31-40. doi: 10.5527/wjn.v4.i1.31.
Chronic kidney disease (CKD) is common and the cause of significant morbidity and mortality. The replacement of functioning nephrons by fibrosis is characteristic of progressive disease. The pathways that lead to fibrosis are not fully understood, although chronic non-resolving inflammation in the kidney is likely to drive the fibrotic response that occurs. In patients with progressive CKD there is histological evidence of inflammation in the interstitium and strategies that reduce inflammation reduce renal injury in pre-clinical models of CKD. The complement system is an integral part of the innate immune system but also augments adaptive immune responses. Complement activation is known to occur in many diverse renal diseases, including glomerulonephritis, thrombotic microangiopathies and transplant rejection. In this review we discuss current evidence that complement activation contributes to progression of CKD, how complement could cause renal inflammation and whether complement inhibition would slow progression of renal disease.
慢性肾脏病(CKD)很常见,是导致严重发病和死亡的原因。纤维化取代功能正常的肾单位是疾病进展的特征。虽然肾脏中慢性 unresolved 炎症可能驱动发生的纤维化反应,但导致纤维化的途径尚未完全了解。在进行性CKD患者中,有间质炎症的组织学证据,并且在CKD临床前模型中,减少炎症的策略可减轻肾损伤。补体系统是固有免疫系统的一个组成部分,但也增强适应性免疫反应。已知补体激活发生在许多不同的肾脏疾病中,包括肾小球肾炎、血栓性微血管病和移植排斥反应。在本综述中,我们讨论了补体激活促进CKD进展的现有证据、补体如何引起肾脏炎症以及补体抑制是否会减缓肾脏疾病进展。